GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kazia Therapeutics Ltd (NAS:KZIA) » Definitions » Book Value per Share

Kazia Therapeutics (Kazia Therapeutics) Book Value per Share : $0.36 (As of Jun. 2023)


View and export this data going back to 1999. Start your Free Trial

What is Kazia Therapeutics Book Value per Share?

Kazia Therapeutics's book value per share for the quarter that ended in Jun. 2023 was $0.36.

During the past 12 months, Kazia Therapeutics's average Book Value Per Share Growth Rate was -61.70% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -29.90% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -28.00% per year. During the past 10 years, the average Book Value Per Share Growth Rate was -14.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Kazia Therapeutics was 68.30% per year. The lowest was -48.10% per year. And the median was -16.60% per year.

Kazia Therapeutics's current price is $0.36995. Its book value per share for the quarter that ended in Jun. 2023 was $0.36. Hence, today's PB Ratio of Kazia Therapeutics is 1.04.

During the past 13 years, the highest P/B Ratio of Kazia Therapeutics was 11.64. The lowest was 0.09. And the median was 2.34.


Kazia Therapeutics Book Value per Share Historical Data

The historical data trend for Kazia Therapeutics's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kazia Therapeutics Book Value per Share Chart

Kazia Therapeutics Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Book Value per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.59 1.03 2.19 0.93 0.36

Kazia Therapeutics Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Book Value per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.19 1.38 0.93 0.48 0.36

Competitive Comparison of Kazia Therapeutics's Book Value per Share

For the Biotechnology subindustry, Kazia Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kazia Therapeutics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kazia Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Kazia Therapeutics's PB Ratio falls into.



Kazia Therapeutics Book Value per Share Calculation

Kazia Therapeutics's Book Value Per Share for the fiscal year that ended in Jun. 2023 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(8.09-0.00)/22.80
=0.35

Kazia Therapeutics's Book Value Per Share for the quarter that ended in Jun. 2023 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(8.09-0.00)/22.80
=0.35

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.


Kazia Therapeutics  (NAS:KZIA) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Kazia Therapeutics Book Value per Share Related Terms

Thank you for viewing the detailed overview of Kazia Therapeutics's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Kazia Therapeutics (Kazia Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
300 Barangaroo Avenue, Level 24, Three International Towers, Sydney, NSW, AUS, 2000
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing innovative anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors.
Executives
Josiah T Austin director, 10 percent owner 4673 CHRISTOPHER PLACE, DALLAS TX 75204
El Coronado Holdings, Llc 10 percent owner 4673 CHRISTOPHER PLACE, DALLAS TX 75204